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1. Introduction 
The lung is continuously exposed to the external environment and mixtures of complex 
antigens through the air. It is estimated that the resting human adult inhales 12,000 liters of 
air per day, while even mild physical activity can double or triple this amount (1). Protective 
immunity against inhaled antigens is mediated by the lymphocytes that are localized to the 
surface of the respiratory tract. The compartments in the lung where lymphocytes are 
present are (i) the epithelium and lamina propria of the air-conducting regions, (ii) the 
bronchus-associated lymphoid tissue (found commonly in certain animals i.e. rabbit and 
rats) (iii) the pulmonary interstitium and vascular beds (iv) the bronchoalveolar space. In 
addition to anatomical barriers, such as airway angulation, mucociliary clearance, and 
coughing, both humoral and cellular defense mechanisms play an important role in 
maintaining the viability of the host. One of the first lines of defense against particulate 
matter is mucociliary clearance and phagocytic activity of alveolar macrophages. Antigens 
entering the pulmonary tract encounter antigen-presenting cells comprised of alveolar and 
interstitial macrophages and effector T lymphocytes. 
2. Bronchoalveolar lavage for diagnosis of various respiratory disorders 
Bronchoscopy with bronchoalveolar lavage (BAL) is an important tool for the diagnosis of 
pulmonary infections and malignancies. Flexible fiberoptic bronchoscopy is a relatively safe 
and minimally invasive means by which to obtain bronchoalveolar lavage fluid (BALF). It is 
usually well tolerated by patients and can be performed safely even on those patients who 
are quite ill.  
The diagnostic and prognostic utility of BAL was first evaluated in the 1980s (2). The 
investigatory technique of BAL has become one of the most valuable research tools for 
studying inflammatory mechanisms in a wide range of diseases that affect the lungs and 
airways in humans. In addition, cytological and microbiological testing of BAL samples are 
of established value for assisting in clinical diagnosis and management of many lung 
diseases, and these procedures are available routinely. 
Since the introduction of the rigid bronchoscope by Dr. Jackson in 1904, BAL is a diagnostic 
procedure in which a fiber-optic bronchoscope is passed through the mouth or nose into the 
lung and fluid is put into a small part of the lung and then recollected for examination. 
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Bronchoalveolar lavage is typically performed to diagnose lung disease. Primarily, BAL was 
used as a treatment for patients who suffered from diseases associated with accumulation of 
purulent secretions such as alveolar proteinosis, cystic fibrosis and bacterial pneumonia (3). 
3. Definition 
By definition BAL is a method for the recovery of cellular and non-cellular components from 
the lower respiratory tract (e.g. alveoli) (4). It is a safe technique, with few major 
complications (5). In many cases (e.g. pulmonary proteinosis, alveolar hemorrhage, 
eosinophilic pneumonia) BAL can replace lung biopsy (6). Possible uses of BAL in 
diagnostics are summarized in following table 
 
Non-infectious Infectious 
Sarcoidosis (Ventilator-associated) pneumonia 
Hypersensitivity pneumonitis Pneumocystis pneumonia 
Idiopatic lung fibrosis Mycobacterial infection 
Connective tissue disorders Aspergillus fumigatus infection 
Langerhans cell histiocytosis Viral pneumonia 
Malignancies Toxoplasma pneumonia 
Alveolar hemorrhage Legionella infection 
Alveolar proteinosis Mycoplasma pneumoniae pneumonia 
Eosinophilic pneumonia Chlamydia pneumoniae pneumonia 
Bronchiolitis obliterans with organizing 
pneumonia 
Cryptococcal infection 
Asbestosis Histoplasma infection 
Silicosis Strongyloides infection  
Table 1. Pulmonary diseases where BALF can be used to a diagnosis (7, 8, 9). 
4. Procedure 
Bronchoalveolar Lavage is a minimally invasive technique which is used to obtain cells, 
inhaled particles, infectious organisms and solutes from the alveolar spaces of the lung. To 
achieve this, a sufficient volume of lavage fluid must be instilled to ensure a sufficient 
aspirate. In adults, a minimum of 100 mL of lavage fluid should be instilled. Besides 
diagnostic BAL, there are other lavage techniques are used and they differ in the following 
ways: 1) Bronchial lavage (or bronchial washing) requires relatively little instilled fluid (10 -
30 mL) and samples from large airways for bacteriological study and/or tumour cytology; 
2) therapeutic lavage usees small volumes and is used to remove sticky bronchial secretions 
in patients with asthma or cystic fibrosis; and 3) whole lung lavage is performed in order to 
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wash out an entire lung in patients with alveolar proteinosis, which requires repeated 
instillation of 1 L of fluid (in total 10–40 L for each lung) through a double-lumen 
endotracheal tube during general anaesthesia. 
BAL is usually performed during fibreoptic bronchoscopy with topical anaesthetic after 
general inspection of the tracheobronchial tree. BAL can also be performed under general 
anaesthesia and in ventilated patients through a rigid bronchoscope or an endotracheal 
tube.  
5. Site of bronchoalveolar lavage 
The site of lavage depends on the localization of the abnormalities. In case of localized 
disease, for instance an infection with a radiographically apparent infiltrate or a malignancy, 
the involved segment should be sampled (10). In diffuse lung disease, the middle lobe or 
lingular lobe is commonly used as a standard site for BAL. This is often the most accessible 
site and the fluid obtained at one site is representative of the whole lung in diffuse lung 
diseases (11). If anatomical difficulties are encountered in both lobes the anterior segment of 
either the upper or lower lobe may be used. Using the method described, approximately 1.5-
3% of the lung (approximately 1,000,000 alveoli) are sampled (4). 
Usually, the lavage is performed using sterile, unbuffered isotonic saline (0.9% NaCl) 
solution and preferably the saline is preheated to body-temperature (37ºC) to help prevent 
coughing and increase cellular yield (12). The volume varies between 100 and 300 ml in 
aliquots of 20 to 50 ml (13). The ERS task force recommended the use of 200-240 ml divided 
in four aliquots.  
5.1 Fluid instillation and recovery 
The fluid is instilled with syringes through the biopsy channel of bronchoscope and 
immediately recovered by applying suction (25-100 mmHg), using a standard number of 
input aliquots of 20–60 mL (commonly four to five aliquots are recommended) up to a total 
volume of 100–300 mL. Smaller instilled volumes (<100 mL) increase the likelihood of 
contamination by the bronchial spaces, including inflammatory cells derived from the larger 
airways, which may skew the differential cell counts [14]. 
The first aspirated volume is normally smaller than the following ones. Usually, 40–70% of 
the instilled volume is recovered. In obstructive airway disease and emphysema the 
recovery rate is significantly lower and may be <30%. The yield is also reduced in healthy 
smokers and the elderly. In addition, fluid recovery may be low with a poor wedge position 
leading to leakage of lavage fluid around the bronchoscope, which is associated with cough. 
Differential evaluation of the ‘‘bronchial’’ (first aliquot) and ‘‘alveolar’’ (subsequent 
aliquots) samples may be useful in airway diseases. Siliconised or plastic containers should 
be used for collection and processing of BAL fluid to avoid loss of cells through adhesion to 
glass surfaces. 
6. Safety aspects 
The BAL procedure is practically associated with no mortality and carries a low 
complication rate of 0–2.3% [15–17]. After BAL procedure there is fever in some hours and a 
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transient decrease in lung function parameters, both usually self-limited and resolving 
within 24 h. These are the most frequent adverse effects and occur in 3–30% of patients, 
depending on the instilled volume. Other adverse effects include short-lasting alveolar 
infiltration, wheezing and bronchospasm in patients with hyper-reactive airways. Major or 
late complications are only seen in patients with severe lung or heart disease, and bleeding 
has only been reported in patients with clotting disorders or thrombocytopenia. Risk factors 
for developing adverse effects are: 1) extensive pulmonary infiltrates, an arterial oxygen 
tension <8.0 kPa (<60 mmHg) and an oxygen saturation <90%; 2) a forced expiratory 
volume in 1 s <1.0 L; 3) prothrombin time >50 s and platelet counts <20,000 platelets/mL; 4) 
significant comorbidity; and 5) bronchial hyperreactivity. 
6.1 Quality control of BALF 
To ensure that the obtained material represents the situation in the alveoli, a number of 
criteria have been established. A BALF is regarded non-representative if it fulfills one of the 
following criteria: i) volume <20 ml, ii) total cell count <60,000 cells/ml, iii) presence of >1% 
squamous epithelial cells, iv) presence of >5% bronchial epithelial cells, v) presence of 
extensive amounts of debris, vi) severely damaged cell morphology. 
6.2 Specimen processing 
The total fluid recovered is kept at room temperature and should be transported to the 
laboratory within 1 hr because the cells are not well preserved in the saline solution. The 
fluid should be pooled into a single container and total volume should be measured. The 
lavage fluid frequently contains large amounts of mucus; therefore, filtration through cotton 
gauze or nylon mesh is often performed. Filtration leads to a preferential loss of bronchial 
epithelial cells without a significant effect on the total cell count and cell differentials. After 
filtration, the fluid is centrifuged for 10 min at 500g and after this the supernatant can be 
stored at -20°C or -70°C for subsequent analysis of soluble components. The total number of 
cells is counted in a haemocytometer, either in a sample of the pooled native fluid or in a 
resuspension of the cells after the first centrifugation. Washing procedures result in a loss of 
total cell count but lead to an increase in cell viability of the remaining cells. The total cell 
count is usually expressed as the total number of cells recovered per lavage but also as the 
concentration of cells per mL of recovered fluid. Cell viability is assessed by trypan blue 
exclusion and should range from 80% to 95% [18, 19]. 
For the enumeration of cell differentials, at least 600 cells are counted on cytocentrifuge or 
cell smear preparations after staining with May-Grunwald-Giemsa stain. A high percentage 
of epithelial cells (>5%) is indicative of contamination of the alveolar samples by bronchial 
cells. At least three unstained slides should be stored so that special stains (iron, periodic 
acid–Schiff (PAS), silver, toluidine blue, fat or Ziehl–Neelsen) can be performed as per need. 
Besides these routine investigations, further work-up can be performed as needed. For 
example, if a tumor is suspected the Papanicolau stain can be applied. If infection is 
suspected, a complete microbiological assessment, including cultures, should be performed. 
To document asbestos exposure, quantitative determination of asbestos bodies can be made 
after vacuum filtration of the native BAL fluid through a 0.45-1.2 µm Millipore membrane. 
The exact dust composition can be determined by electron microscopy with energy 
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dispersive X-ray spectrometry. Lymphocyte subpopulations can be identified by 
immunocytochemical methods, immunofluorescence or flow cytometry using monoclonal 
antibody techniques [20]. 
These investigations are not recommended as a routine procedure for all BAL specimens. They 
are indicated in cases with high lymphocyte counts, such as extrinsic allergic alveolitis, or if 
Langerhans cell histiocytosis is suspected CD3. CD4, CD8, CD20 and markers of T-cell activation 
can be determined. CD1a or Langerin are very specific markers of Langerhans cell histiocytosis. 
Flow cytometry is also a useful tool to detect markers of malignant lymphoma [21]. 
There are some studies also performed for research purposes including functional studies of 
viable BAL cells, cell cultivation in appropriate culture medium and determination of 
mediators along with the mechanisms that appear to regulate the mediator release. Cells can 
also be probed with molecular biology to investigate gene activation and intracellular 
signaling pathways. 
7. Normal values of BAL in healthy volunteers 
The BAL fluid obtained from healthy, nonsmoking adults without lung disease contains 
only small percentages of lymphocytes, neutrophils and other inflammatory cells; alveolar 
macrophages are the predominant cell population (80–90%) (fig. 1a). Differential cell count 
in healthy non-smokers have been reported to show macrophages >80%, lymphocytes ≤15%, 
neutrophils ≤3%, eosinophils ≤0.5%, and mast cells ≤0.5%. 
  
          (a)                (b) 
Fig. 1. Bronchoalveolar lavage in a) a healthy nonsmoker and b) a healthy smoker [22]. 
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Cigarette smoking is a strong confounding factor with significant effects on BAL samples. 
The alveolar macrophages from smokers show a 3 to 5 fold increase and characteristic 
morphology: many of them are much larger than those in nonsmokers and contain 
cytoplasmic inclusion bodies (smoker’s inclusion bodies) consisting of tar products, lipids, 
lipofuscin and other substances (fig. 1b). 
7.1 BAL in the diagnosis of diffuse parenchymal lung disease 
BAL is indicated in every patient with nuclear pulmonary shadowing or interstitial lung 
disease (ILD). BAL findings may be very specific, so that they can directly confirm a 
particular diagnosis. BAL should not be considered as a stand-alone diagnostic test and 
should be interpreted in the context of clinical, laboratory and radiographical high 
resolution computed tomography (HRCT) findings. It has been used in diagnostic and 
prognostic evaluation in diffuse parenchymal lung disease for three decades and has a 
central role in the diagnosis of a number of rare disorders and in excluding opportunistic 
infection in treated patients. It also has an important role in the diagnosis of many prevalent 
disorders, including sarcoidosis, hypersensitivity pneumonitis and idiopathic pulmonary 
fibrosis. 
7.2 Specific BAL findings in rare diseases 
7.2.1 Pulmonary alveolar proteinosis 
Pulmonary alveolar proteinosis is one of the few diseases in which BAL can confirm the 
diagnosis and replace lung biopsy. In pulmonary alveolar protienosis the BAL fluid is 
macroscopically milky and turbid. Under light microscopy the characteristic acellular oval 
bodies (surfactant derived lipoproteins) are basophilic on May-Grunwald-Giemsa staining 
and positive with PAS staining. The background is occupied by large amounts of 
amorphous debris showing weak PAS staining and a few foamy macrophages [21]. 
7.2.2 Langerhans cell histiocytosis 
Pulmonary Langerhans cell histiocytosis is strongly associated with cigarette smoking, and 
the BAL differential shows the typical smoker’s constellation with increased total cell counts 
and macrophages with smoker’s inclusions. The specific finding is an increase in 
Langerhans cells to >4% of the total BAL cell count. The sensitivity is low because in late 
cases of the disease the number of Langerhans cells decrease in the tissue. Low proportions 
of Langerhans cells in the range of 2-4% can be seen in other conditions, such as in healthy 
smokers, respiratory bronchiolitis/interstitial lung disease (RB/ILD), other ILD and 
bronchioalveolar carcinoma [21]. The Langerhans cells can be easily identified in BAL by 
their staining with the monoclonal antibody for CD1a or Langerin [23]. The intracytoplasmic 
reaction with polyclonal antibody S100 is not as specific. As in alveolar proteinosis, 
electronic microscopy is not recommended as a routine diagnostic procedure. 
7.2.3 Diffuse alveolar haemorrhage 
Diffuse alveolar haemorrhage (DAH) is a clinical syndrome with widespread bleeding into 
the alveolar space as a result of multiple causes. The demonstration of numerous 
www.intechopen.com
 
Role of Broncoalveolar Lavage in Diagnosis 
 
63 
haemosiderin-laden macrophages on BAL cytology enables a diagnosis to be made even in 
cases with occult bleeding. In patients with fresh bleeding episodes free red blood cells in 
the fluid and fragments of ingested red blood cells within the cytoplasm of macrophages are 
pathognomonic. 
To asses the severity of bleeding, the percentage of siderophages can easily be counted. It 
has been shown that a percentage of siderophages ≥20% is sufficient for a diagnosis of DAH. 
Many syndromes belong to this group and other clinical and laboratory findings must be 
investigated to establish the cause of the bleeding. In the clinical setting, chronic left heart 
failure with pulmonary congestion is one of the most frequent underlying conditions for the 
finding of DAH in BAL fluid examination. Endogenous bleeding has to be differentiated 
from exogenous iron load of the lungs. Exogenous siderosis does not show roundish 
fragments of erythrocytes but irregular shaped dust particles engulfed by macrophages. 
7.2.4 Chronic aspiration 
In the differential diagnosis of recurrent pneumonia, gastro-oesophageal reflux with 
aspiration needs to be considered. The BAL cell differential may show a mixed pattern with 
increase in lymphocytes, neutrophils and eosinophils. The characteristic diagnostic finding 
is the presence of large numbers of lipid-laden macrophages and is highly suggestive of 
lipoid pneumonia caused by chronic aspiration. 
7.2.5 Pneumoconioses 
In ILD due to mineral dust exposure, BAL can confirm exposure by the detection of dust 
particles in alveolar macrophages. It is of two types: 
a. Asbestos-related disease: Asbestos bodies in BAL fluid can be detected by smear 
technique or cytocentrifuge technique. However quantification of asbestos bodies by a 
specific Millipore filtration is a more sensitive technique. The results are expressed as 
number of asbestos bodies per mL of BAL fluid, which shows a relatively good 
correlation with the asbestos body count in lung tissue analysis. However, 10–15% of 
subjects with known occupational asbestos exposure may have no detectable asbestos 
bodies in their BAL fluid. Thus, a negative BAL asbestos body count does not exclude 
asbestos-related disease. 
b. Chronic beryllium disease: This condition is clinically, radiologically and histologically 
identical to sarcoidosis and in this condition BAL lymphocytes have an increase in the 
CD4/CD8 ratio . Because the antigen is known, a diagnostic in vitro lymphocyte 
transformation test can be performed. Lymphocytes from blood or BAL fluid are 
incubated with beryllium salts and the beryllium-specific proliferation of the 
lymphocytes is quantified. A positive lymphocyte transformation test of BAL T-cells to 
beryllium salts is highly sensitive and specific (definitely more sensitive than the blood 
test) and always recommended in doubtful cases to confirm the diagnosis. 
7.2.6 Eosinophilic lung disease 
Eosinophilic lung disease can be diagnosed when there are ≥25% eosinophils in BAL of the 
radiologically affected segment. In both acute and chronic eosinophilic pneumonia the 
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fraction of BAL eosinophils ranges from 20% to 90% and is higher than the neutrophil 
fraction. In this condition a mild-to-moderate increase in lymphocyte count with a decrease 
in CD4/CD8 ratio can be observed. In combination with clinical and HRCT findings, 
eosinophilic lung diseases can be appropriately diagnosed by BAL alone without an open 
lung biopsy [21]. 
7.2.7 Opportunistic infections 
BAL has achieved the greatest diagnostic value among immunocompromised patients with 
pulmonary infiltrates. The sensitivity of BAL ranges from 60–90% in the diagnosis of 
bacterial infections, 70–80% in mycobacterial, fungal and most viral infections, and from 90–
95% in Pneumocystis carinii pneumonia. The characteristic cysts of Pneumocystis can be 
detected on May-Grunwald-Giemsa stained slides. 
In cytomegalovirus pneumonia, the characteristic cytomegalic-transformed cell (the owl eye 
cell) with typical nuclear or cytoplasmic inclusions is highly specific and can be seen on light 
microscopy in 30–50% of cases.  
7.2.8 Malignancies 
BAL is not as sensitive for solid tumours as biopsy and cytology techniques. Diffuse 
malignant infiltrates can be reliably diagnosed in 60–90% of cases. The highest yield is seen 
in widespread malignancies, such as primary bronchoalveolar carcinoma or lymphangitic 
carcinomatosis due to adenocarcinoma. It can also provide diagnostic cytological material in 
haematological malignancies of the lung, including Hodgkin’s disease, non-Hodgkin 
lymphoma, leukaemia, Waldenstrom’s macroglobulinaemia, myeloma and mycosis 
fungoides. In malignant B-cell lymphoma the immunocytological demonstration of a 
monoclonal B-cell population, expressing only one immunoglobulin type and either kappa 
or lambda light chains, can confirm the diagnosis of malignancy [24, 25]. 
8. BAL as an adjunct to diagnosis 
There are no specific BAL findings in the more common interstitial lung diseases. However, 
when BAL cellular analysis is considered in the context of clinical and HRCT findings it may 
contribute to narrowing the differential diagnosis and to avoiding open lung biopsy. BAL 
cellular patterns can generally differentiate the fibrosing conditions (characterised by 
neutrophilia and eosinophilia) from granulomatous diseases (lymphocytosis with or 
without granulocytosis).  
8.1 Sarcoidosis 
In sarcoidosis, BAL shows lymphocytic alveolitis in 90% of patients at the time of diagnosis, 
independent of the stage of sarcoidosis. It was shown that the patients with active 
sarcoidosis have a tendency to show higher lymphocyte counts than those with inactive 
sarcoidosis. However, in the late stage of sarcoidosis neutrophils may also be increased, as 
well as the number of mast cells. Patients with primary extrathoracic sarcoidosis may show 
typical findings of sarcoidosis on BAL even when imaging findings are normal [26]. The 
CD4/CD8 ratio also has high variability in sarcoidosis and approximately only 55% of 
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patients show an increased CD4/CD8 ratio at the time of diagnosis. The ratio is even 
decreased to 1.0 in 15% of patients. The CD4/CD8 ratio is especially high in patients with 
Lofgren syndrome and acute sarcoidosis. Some studies have demonstrated an increased 
neutrophil count in BAL obtained from newly diagnosed patients with sarcoidosis. 
8.2 Extrinsic allergic alveolitis 
This disease shows the highest total cell count and the highest lymphocyte count of all 
ILD’s. The total cell yield is usually >20 million from a 100-mL BAL, with the proportion of 
lymphocytes exceeding 50%. The number of activated T-cells is also increased. The 
assessment of the CD4/CD8 ratio has produced contradictory findings. It is a general belief 
that the CD4/CD8 ratio is decreased. However, more recent studies have demonstrated that 
the ratio may be decreased, normal or increased [27, 28]. The alveolar macrophages are 
heterogeneous and often show a foamy cytoplasm. In acute episodes of extrinsic allergic 
alveolitis, the neutrophil count may increase transiently for approximately one week. A 
normal cell appearance or an isolated increase in neutrophil or eosinophil count widely 
excludes extrinsic allergic alveolitis. 
8.3 Drug induced pneumonitis 
There are a large number of drugs which may induce an ILD, mediated by either toxic or 
immunological mechanisms (Table 2) [29]. Along with BAL lymphocytosis and/or 
granulocytosis, cytotoxic reactions with atypical type II pneumocytes or diffuse alveolar 
haemorrhage may be observed. The most frequent finding is lymphocytic alveolitis with a 
dominance of CD8+ T-cells. Methotrexate-induced pneumonitis may show an increase in 
CD4+ cells. Characteristic changes in amiodarone-induced pneumonitis are the presence of 
alveolar macrophages with a finely vacuolated foamy cytoplasm. These are also seen in 
patients without clinical signs of ILD. If no foamy macrophages are found, amiodarone-
induced pneumonitis can probably be excluded. The BAL findings described are not specific 
for drug-induced lung disease; therefore, additional assessment including tests like anti-
histone antibody is necessary to make the diagnosis. 
8.4 Idiopathic pulmonary fibrosis and other idiopathic interstitial pneumonias 
The typical BAL findings in idiopathic pulmonary fibrosis (IPF) is a moderately increased 
neutrophil count (10-30% of the total cells), with or without an increased eosinophil count. 
In total, 70–90% of the patients show an increased neutrophil count, while 40–60% shows an 
additionally increased eosinophil count. In 10–20% of the patients, a moderately increased 
lymphocyte count (proportion <30%) is seen . 
In nonspecific interstitial pneumonia (NSIP), a BAL lymphocytosis with a mild increase in 
the neutrophil and eosinophil count can be seen [30]. A BAL lymphocytosis is likely to be 
found more frequently in cellular NSIP than in fibrotic NSIP. The BAL findings in cellular 
NSIP appear to resemble those in bronchiolitis obliterans organizing pneumonia (BOOP). 
In acute interstitial pneumonia the histological finding of diffuse alveolar damage shows an 
extremely unfavourable prognosis. The BAL fluid in acute interstitial pneumonia is mostly 
bloody and rich in albumin, indicating increased alveolar capillary permeability. The typical  
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Lymphocytosis Eosinophilia Neutrophilia Cytotoxic reaction Haemorrhage 
Methotrexate Bleomycin Bleomycin Bleomycin D-Penicillamine 
Azathioprine Nitrofurantoin Minocycline Methotrexate Amphotericin B 
Cyclophosphamide Cotrimazole Amiodarone Nitrosoureas Cytotoxic drugs 
Bleomycin Penicillin  Busulfan  
Busulfan Sulfasalazine  Cyclophosphamide  
Vincristine Ampicillin    
Nitrofurantoin Tetracycline    
Minocycline Maloprim    
Gold Minocycline    
Sulfasalazine L-Tryptophan    
Amiodarone     
Acebutolol     
Atenolol     
Celiprolol     
Propranolol     
Flecainide     
Diphenylhydantoin     
Nilutamide     
Table 2. Bronchoalveolar lavage findings in drug-induced interstitial lung disease 
cellular BAL finding is a marked increase in neutrophils and an occasional increase in 
lymphocytes. Atypical pneumocytes mimicking adenocarcinoma and fragmented hyaline 
membranes may also be observed [25]. The typical BAL findings in desquamative interstitial 
pneumonia and RB/ILD are an increase in macrophages with black pigmented inclusions. 
In this an increase in neutrophils, eosinophils and, occasionally, lymphocytes may also be 
seen. Idiopathic lymphocytic interstitial pneumonia is rare and is usually associated with 
collagen vascular diseases, Sjogren’s syndrome or lymphoma. The typical BAL finding in 
lymphocytic interstitial pneumonia is lymphocytosis and CD4/CD8 ratio shows diverse 
alterations. 
8.5 Collagen vascular disease 
In collagen vascular diseases (CVD), pulmonary involvement can be associated with 
various histopathological patterns. The pathology may be similar to IPF with a usual 
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interstitial pneumonia pattern, but many of the cases of CVD-associated pulmonary 
fibrosis show a pattern that is in the category of NSIP, based on a computed tomography 
scan or histology [26]. The BAL findings are also somewhat different from IPF. The 
general pattern is increased neutrophils, with or without eosinophils, but increased 
lymphocytes are more commonly seen than in IPF [31]. In general, BAL seems to have a 
limited value in the diagnosis of CVD affecting the lungs because the BAL profile is very 
nonspecific. However, BAL may be useful in detecting other pulmonary problems that 
may arise in these disorders, including drug induced toxicity, infection, pulmonary 
haemorrhage associated with vasculitis and malignancy. The NSIP pattern was the more 
prevalent pattern. It has previously been shown that increased BAL neutrophils were 
associated with more extensive changes on HRCT. An abnormal BAL may be the first 
evidence of pulmonary involvement in CVD. If radiographic signs are absent and 
pulmonary function tests are normal, this abnormal finding indicates subclinical 
alveolitis. It is still not clear whether such subclinical alveolitis needs treatment. It is also 
not clear whether the pattern of BAL cells (increase in neutrophils or lymphocytes) in a 
setting of subclinical alveolitis reflects the prognosis [32]. 
9. Role of BAL in the prognosis and activity of disease 
It is unclear whether BAL cellularity is useful for assessing the activity of disease processes 
with respect to obtaining prognostic information. In sarcoidosis, differences were observed 
for several BAL parameters between clinically active and inactive patient groups, but 
without predicting long-term outcome in individual patients. It is not proven that BAL or 
serial BAL is useful to guide therapy or predict treatment response. At present, BAL cannot 
be routinely recommended for this purpose. 
10. Role of BAL in research and development of new drugs 
The discovery of new signal pathways and biomarkers between cells and the application of 
proteomics, gene arrays and metabolomics has contributed many important insights into the 
pathogenesis of respiratory tract diseases. BAL has been profiled as a fundamental method 
to obtaining alveolar space and airway specimens for research, and this could lead to more 
clear-cut longitudinal monitoring of ILD in the future. For example, KL-6, a high-molecular 
weight glycoprotein predominantly expressed on the surface of alveolar type II cells, is a 
promising biomarker in the field of ILD. Increased levels of KL-6 in BAL fluid and plasma 
correlate with the severity of alveolar inflammation and poor survival in acute respiratory 
distress syndrome [33]. Increased levels of KL-6 in both BAL fluid and blood, with a strong 
correlation between BAL and blood, also reflect disease severity in patients with idiopathic 
pulmonary alveolar proteinosis [34]. BAL is suitable for studying the cellular and biological 
changes induced by drugs. In this view, BAL can be used for concept studies in the clinical 
development of new drugs. 
11. Conclusion 
Bronchoalveolar lavage is an easily performed and well tolerated procedure able to provide 
cellular contents, cellular products, and proteins from the lower respiratory tract. 
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In the rapidly evolving field of pulmonary diagnostic tests, BAL has a specific value for 
the diagnosis of certain ILD’s, such as alveolar proteinosis, Pneumocystis pneumonia, 
bronchoalveolar carcinoma, malignant non-Hodgkin lymphoma and alveolar 
haemorrhage, allowing surgical lung biopsy to be avoided. In other ILD’s, BAL findings 
may be able, in combination with clinical and HRCT findings, to strengthen or weaken a 
suspected diagnosis. This method is also valid support for research. Genetic and 
molecular biomarkers, with different diagnostic/prognostic significance, can be detected 
in BAL. 
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